Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome: Bursa Uludag University Experience

Authors : İbrahim Ethem PINAR, Fahir ÖZKALEMKAŞ, Vildan OZKOCAMAN, Tuba ERSAL, Cumali YALÇIN, Bedrettin ORHAN, Ömer CANDAR

Pages : 42-43

Doi:10.46310/tjim.877068

View : 11 | Download : 10

Publication Date : 2021-03-07

Article Type : Other Papers

Abstract :The management of acute myeloid leukemia insert ignore into journalissuearticles values(AML); gradually turns into an individualized approach with the application of targeted therapies. Venetoclax is a BCL-2 inhibitor that is synergistic with azacitidine. In this case series, 14 patients diagnosed with relapsed / refractory AML and 1 MDS RAEB-1 were followed up with venetoclax + azacitidine in the Hematology Department Bursa Uludag University Faculty of Medicine were evaluated. The best responses obtained with venetoclax + azacitidine were complete remission insert ignore into journalissuearticles values(CR); in one patient, complete remission with incomplete hematologic recovery insert ignore into journalissuearticles values(CRi); in one patient, morphological leukemia-free state insert ignore into journalissuearticles values(MLFS); in 4 patients, and partial response insert ignore into journalissuearticles values(PR); in one patient. The median time to first response with treatment was one month insert ignore into journalissuearticles values(0.5-5);. The time to enter early remission is critical. For this reason, deaths due to infection should be prevented. Although the toxicities of this combination therapy can be managed, close follow-up of the patients is mandatory. In conclusion, this combination therapy is promising as it is relatively well-tolerated, improves the quality of life, and prolongs survival.
Keywords : Venetoclax, azacitidine, acute myeloid leukemia, myelodysplastic syndrome